As the dust settles from the U.S. Food and Drug Administration's approval of the first-ever study of a treatment based on human embryonic stem cells, researchers are now assessing what this trial may mean for the years to come in stem cell research -- and how the politics of the past decade may have damaged their progress.
Researchers are hopeful that President-elect Barack Obama will make good on his promise to lift the long-standing ban on federal funding for embryonic stem cell research.
The study, for which California based Geron Corp. won FDA approval on Friday, will examine the potential of an embryonic stem cell treatment in fixing severe spinal cord injuries in humans.
For proponents of stem cell research, the double impact of the first-of-its-kind trial and an administration that appears open to exploiting the potential of embryonic stem cells is a promising sign that progress is finally on its way.
"I am in favor of anything that will bring us closer to a cure for diseases like Alzheimer's and diabetes," said former first lady Nancy Reagan in a statement issued Friday in response to news of the study. Reagan emerged as a prominent supporter of stem cell research after her husband, President Ronald Reagan, passed away in 2004 after a 10-year battle with Alzheimer's disease.